Phase II trial of gemcitabine and docetaxel in androgen-independent metastatic prostate cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Gemcitabine (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Jan 2013 Biomarkers information updated
- 05 Jun 2012 Actual patient number 35 and lead trial centre added as reported by ClinicalTrials.gov.
- 11 Feb 2011 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.